LncRNA landscape analysis identified LncRNA LEF-AS1 as an oncogene that upregulates LEF1 and promotes survival in chronic lymphocytic leukemia

Du, Xiaonan; Liu, Hailing; Yang, Changqing; Shi, Xiao; Cao, Lei; Zhao, Xiaoli; Miao, Yi; Zhu, Huayuan; Wang, Li; Xu, Wei; Li, Jianyong; Fan, Lei

doi:10.1016/j.leukres.2021.106706

Cited by 8 publications

(4 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…demonstrated that NCK1-AS1 promoted lung squamous cell carcinoma progression (LUSC) by upregulating NCK1 through interaction with MYC. It has been shown that antisense lncRNAs play a cis-regulatory role in sense mRNAs (50)(51)(52). Antisense lncRNAs located in the nucleus can recruit DNA, histonemodifying enzymes, or transcription factors to specific sites to cis-regulate the expression of sense mRNAs (53).…”

Section: Discussionmentioning

confidence: 99%

LncRNA FOXP4-AS1 Promotes the Progression of Esophageal Squamous Cell Carcinoma by Interacting With MLL2/H3K4me3 to Upregulate FOXP4

Niu

Wang

et al. 2021

Front. Oncol.

View full text Add to dashboard Cite

Malignant tumors are a grave threat to human health. Esophageal squamous cell carcinoma (ESCC) is a common gastrointestinal malignant tumor. China has a high incidence of ESCC, and its morbidity and mortality are higher than the global average. Increasingly, studies have shown that long noncoding RNAs (lncRNAs) play a vital function in the occurrence and development of tumors. Although the biological function of FOXP4-AS1 has been demonstrated in various tumors, the potential molecular mechanism of FOXP4-AS1 in ESCC is still poorly understood. The expression of FOXP4 and FOXP4-AS1 was detected in ESCC by quantitative real-time PCR (qRT–PCR) or SP immunohistochemistry (IHC). shRNA was used to silence gene expression. Apoptosis, cell cycle, MTS, colony formation, invasion and migration assays were employed to explore the biological functions of FOXP4 and FOXP4-AS1. The potential molecular mechanism of FOXP4-AS1 in ESCC was determined by dual-luciferase reporter, RNA immunoprecipitation (RIP) and chromatin immunoprecipitation (ChIP). Here, we demonstrated that FOXP4-AS1 was significantly increased in ESCC tissues and cell lines, associated with lymph node metastasis and TNM staging. Cell function experiments showed that FOXP4-AS1 promoted the proliferation, invasion and migration ability of ESCC cells. The expression of FOXP4-AS1 and FOXP4 in ESCC tissues was positively correlated. Further research found that FOXP4-AS1, upregulated in ESCC, promotes FOXP4 expression by enriching MLL2 and H3K4me3 in the FOXP4 promoter through a “molecular scaffold”. Moreover, FOXP4, a transcription factor of β-catenin, promotes the transcription of β-catenin and ultimately leads to the malignant progression of ESCC. Finally, FOXP4-AS1 may be a new therapeutic target for ESCC.

show abstract

Section: Discussionmentioning

confidence: 99%

LncRNA FOXP4-AS1 Promotes the Progression of Esophageal Squamous Cell Carcinoma by Interacting With MLL2/H3K4me3 to Upregulate FOXP4

Niu

Wang

et al. 2021

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…In a cohort of newly diagnosed CLL patients, LEF1-AS1 was found to be up-regulated in comparison to healthy controls, but the association with baseline patients' characteristics and established prognostic markers was not observed [128]. Overexpression of LEF1-AS1 in CLL cell lines via lentiviral transduction resulted in increased survival and inhibition of apoptosis, implying its oncogenic role in CLL.…”

Section: Lncrna Lef1-as1mentioning

confidence: 87%

“…In AML, it was shown that increased expression of MEG3 is a reliable molecular marker of favorable prognosis, both in pediatric and adult patients. In adult de novo AML patients, high MEG3 expression was independent predictor for longer DFS and OS [128], while in pediatric de novo AML patients increased MEG expression was associated with prolonged OS [133,134]. High MEG3 expression in AML patients after induction therapy was also associated with better DFS and OS, indicating that it could be used as a marker for the prediction of therapy response.…”

Section: Lncrna Meg3mentioning

confidence: 96%

See 1 more Smart Citation

Diagnostic and Therapeutic Implications of Long Non-Coding RNAs in Leukemia

Gašić

Karan-Djurašević

Pavlovic

et al. 2022

Life

View full text Add to dashboard Cite

Leukemia is a heterogenous group of hematological malignancies categorized in four main types (acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic myeloid leukemia (CML) and chronic lymphocytic leukemia (CLL). Several cytogenetic and molecular markers have become a part of routine analysis for leukemia patients. These markers have been used in diagnosis, risk-stratification and targeted therapy application. Recent studies have indicated that numerous regulatory RNAs, such as long non-coding RNAs (lncRNAs), have a role in tumor initiation and progression. When it comes to leukemia, data for lncRNA involvement in its etiology, progression, diagnosis, treatment and prognosis is limited. The aim of this review is to summarize research data on lncRNAs in different types of leukemia, on their expression pattern, their role in leukemic transformation and disease progression. The usefulness of this information in the clinical setting, i.e., for diagnostic and prognostic purposes, will be emphasized. Finally, how particular lncRNAs could be used as potential targets for the application of targeted therapy will be considered.

show abstract

Advances in epigenetic alterations of chronic lymphocytic leukemia: from pathogenesis to treatment

Zhang,

Wang,

Zhang

et al. 2024

Clin Exp Med

View full text Add to dashboard Cite

Chronic lymphocytic leukemia (CLL) is a heterogeneous disease with alterations in genetic expression and epigenetic modifications. In recent years, the new insight into epigenetics in the pathogenesis of CLL has been developed considerably, including DNA methylation, histone modification, RNA methylation, non-coding RNAs as well as chromatin remodeling. Epigenetic modification regulates various processes such as stem cell biology, cell growth, and tumorigenesis without altering gene sequence. Growing evidence indicates that the disturbance of gene expression profiles which were regulated by epigenetic modifications exerts vital roles in the development and progress in CLL, which provides novel perspectives to explore the etiology of CLL. In addition, the integration with epigenetic therapeutic targets and the in-depth understanding of epigenetic therapy contribute to develop new therapeutic strategies for CLL. Herein, the present review discusses the advances of epigenetic alterations in the pathogenesis, diagnosis, and prognostic assessment of CLL patients and also highlights existing and emerging agents targeting epigenetic regulators.

show abstract

LncRNA landscape analysis identified LncRNA LEF-AS1 as an oncogene that upregulates LEF1 and promotes survival in chronic lymphocytic leukemia

Cited by 8 publications

References 22 publications

LncRNA FOXP4-AS1 Promotes the Progression of Esophageal Squamous Cell Carcinoma by Interacting With MLL2/H3K4me3 to Upregulate FOXP4

LncRNA FOXP4-AS1 Promotes the Progression of Esophageal Squamous Cell Carcinoma by Interacting With MLL2/H3K4me3 to Upregulate FOXP4

Diagnostic and Therapeutic Implications of Long Non-Coding RNAs in Leukemia

Advances in epigenetic alterations of chronic lymphocytic leukemia: from pathogenesis to treatment

Contact Info

Product

Resources

About